Acute monoblastic leukemia

Acute Monoblastic Leukemia with t(11;17)(q23;q21): Fusion of the KMT2A(MLL) and MLLT6(AF17) Genes

Laboratory Medicine Online ◽

10.3343/lmo.2019.9.4.258 ◽

2019 ◽

Vol 9 (4) ◽

pp. 258

Author(s):

Cheon-Gang Park ◽

Seon-Ho Mun ◽

A-Jin Lee ◽

Chang-Ho Jeon ◽

Hun Suk Suh ◽

...

Keyword(s):

Acute Monoblastic Leukemia

A heparin-like anticoagulant in an 8-month-old boy with acute monoblastic leukemia

American Journal of Hematology ◽

10.1002/ajh.2830160111 ◽

1984 ◽

Vol 16 (1) ◽

pp. 83-90 ◽

Cited By ~ 17

Author(s):

James B. Bussel ◽

Peter G. Steinherz ◽

Denis R. Miller ◽

Margaret W. Hilgartner

Keyword(s):

Acute Monoblastic Leukemia

Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia

Blood ◽

10.1182/blood.v98.12.3492 ◽

2001 ◽

Vol 98 (12) ◽

pp. 3492-3494 ◽

Cited By ~ 29

Author(s):

Udomsak Bunworasate ◽

Hilal Arnouk ◽

Hans Minderman ◽

Kieran L. O'Loughlin ◽

Sheila N. J. Sait ◽

...

Keyword(s):

Myelodysplastic Syndrome ◽

Bone Marrow Cells ◽

Tritiated Thymidine ◽

Flow Cytometric Analysis ◽

Refractory Anemia ◽

Laboratory Findings ◽

Flow Cytometric ◽

Acute Monoblastic Leukemia ◽

Leukemia Cutis ◽

Marrow Cells

Abstract Acute monoblastic leukemia (acute myeloid leukemia [AML], French-American-British type M5a) with leukemia cutis developed in a patient 6 weeks after the initiation of erythropoietin (EPO) therapy for refractory anemia with ringed sideroblasts. AML disappeared from both marrow and skin after the discontinuation of EPO. Multiparameter flow cytometric analysis of bone marrow cells demonstrated coexpression of the EPO receptor with CD45 and CD13 on the surface of blasts. The incubation of marrow cells with EPO, compared to without, resulted in 1.3- and 1.6-fold increases, respectively, in tritiated thymidine incorporation and bromodeoxyuridine incorporation into CD13+ cells. Clinical and laboratory findings were consistent with the EPO-dependent transformation of myelodysplastic syndrome (MDS) to AML. It is concluded that leukemic transformation in patients with MDS treated with EPO may be EPO-dependent and that management should consist of the discontinuation of EPO followed by observation, if clinically feasible.

Biclonal acute monoblastic leukemia showing del(7q) and trisomies 9 and 22

Cancer Genetics and Cytogenetics ◽

10.1016/0165-4608(94)00227-3 ◽

1995 ◽

Vol 82 (1) ◽

pp. 70-72 ◽

Cited By ~ 5

Author(s):

K.F. Wong ◽

Y.L. Kwong ◽

K.C. Tang

Keyword(s):

Acute Monoblastic Leukemia

Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung

Blood ◽

10.1182/blood.v70.5.1412.bloodjournal7051412 ◽

1987 ◽

Vol 70 (5) ◽

pp. 1412-1417 ◽

Cited By ~ 2

Author(s):

MJ Ratain ◽

LS Kaminer ◽

JD Bitran ◽

RA Larson ◽

MM Le Beau ◽

...

Keyword(s):

Combination Chemotherapy ◽

Advanced Nsclc ◽

De Novo ◽

Cumulative Risk ◽

Late Complications ◽

Small Cell ◽

First Year ◽

Acute Nonlymphocytic Leukemia ◽

Acute Monoblastic Leukemia ◽

High Doses

Combination chemotherapy is frequently used in the therapy of advanced non-small-cell lung cancer (NSCLC), but late complications are rarely recognized because of the short survival of most patients. Of 119 patients with advanced NSCLC treated with cisplatin and other drugs, four patients developed acute nonlymphocytic leukemia (ANLL). All four patients received etoposide and cisplatin with or without vindesine. Leukemia was diagnosed at 13, 19, 28, and 35 months after start of treatment. Three patients had morphologic and/or cytogenetic features of acute leukemia with significant monoblastic involvement; the fourth patient had trilineage dysplasia and cytogenetic abnormalities more commonly associated with therapy-related leukemia. Detailed analysis of the subgroup who survived longer than 1 year (24 patients) suggests that high cumulative doses of etoposide are leukemogenic; the median etoposide dose was 6,795 mg/m2 (first year only) in the four leukemic patients compared with 3,025 mg/m2 in the 20 nonleukemic patients (P less than .01). The rate of ANLL was 0.30 per person-year after the first year (95% confidence limits 0.11 to 0.90), with a cumulative risk of 15% +/- 11% at 2 years, and 44% +/- 24% at 2.5 years. We conclude that high doses of etoposide are potentially leukemogenic, and can induce a syndrome with features of acute monoblastic leukemia de novo that is distinct from other secondary leukemias.

LEUKEMIC BLAST CELLS AND CONTROVERSIES IN MODELS OF HEMATOPOIESIS

Experimental Oncology ◽

10.31768/2312-8852.2015.37(1):2-4 ◽

2015 ◽

Vol 37 (1) ◽

pp. 2-4 ◽

Cited By ~ 1

Author(s):

D F Gluzman ◽

L M Sklyarenko ◽

M P Zavelevich ◽

S V Koval ◽

T S Ivanivskaya

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Lymphoblastic Leukemia ◽

Leukemic Blast ◽

Acute Leukemias ◽

Cell Lineages ◽

Hematopoietic Lineage ◽

Acute Monoblastic Leukemia ◽

Blast Cells ◽

The Common ◽

Insight Into

Classical and up-to-date models of hematopoietic lineage determination are briefly reviewed with the focus on myeloid-based models challenging the existence of the common progenitor for T cells, B cells and NK cells. The analysis of immunophenotype of leukemic blast cells seems to be a promising approach for interpreting some controversies in the schemes of normal hematopoiesis. The liter ature data as well as our own findings in the patients with various types of acute leukemias are in favor of the concept postulating that common myeloid-lymphoid progenitors giving rise to T and B cell branches retain the myeloid potential. The similarity of some immunophenotypic features of blast cells in pro-B acute lymphoblastic leukemia and acute monoblastic leukemia is consistent with monocyte origin postulated in the studies of normal hematopoiesis. Study of acute leukemias may be the challenging area of research allowing for new insight into the origin of hematopoietic cell lineages.

Acquired Chromosome Rearrangements, Including Fine Interstitial Deletions, in a Patient with Down Syndrome and Monoblastic Leukemia

PEDIATRICS ◽

10.1542/peds.74.6.1029 ◽

1984 ◽

Vol 74 (6) ◽

pp. 1029-1033

Author(s):

Shinichi Misawa ◽

Joseph R. Testa ◽

Lewis C. Strauss ◽

Richard D. Leavitt ◽

Curt I. Civin

Keyword(s):

Down Syndrome ◽

Acute Leukemia ◽

Trisomy 21 ◽

Female Child ◽

Chromosome Rearrangements ◽

Leukemic Cells ◽

Structural Rearrangements ◽

Time Analysis ◽

Acute Monoblastic Leukemia ◽

Cytogenetic Studies

A female child with Down syndrome who developed acute monoblastic leukemia is reported. Anemia associated with milk leukopenia was first recognized when the patient was 14 months old. Acute monoblastic leukemia was diagnosed 1 year later; cytogenetic studies were performed on circulating leukemic cells at this time. Analysis of elongated, finely banded chromosomes revealed three structural rearrangements, including two rather subtle interstitial deletions, in addition to trisomy 21 which was representative of the patient's constitutional karyotype. The karyotype of the leukemic cells was 47,XX,+21,t(3;18)(p23;q11.2), del(7)(q31.1q31.3), del(9)(p22p24 or p21p23). The patient received no cytostatic chemotherapy and died 4 months after the diagnosis of acute leukemia was made.